2019 Top 100 Medical Device Companies, 5 Chinese Companies Selected

　　Recently, QMED released the 2019 Top 100 List of Medical Device Companies, which ranks the world's medical device companies based on their revenue in 2019
According to statistics, the top 10 medical device companies in the total revenue of 194.428 billion U.S dollars, a total of 51 medical device companies in the world with revenue of more than $1 billion It is worth noting that five medical device companies in China are on the list: Murray Medical (42), Xinhua Medical (58), Lepu Medical (61), Micro-Invention Medical (80), and Fish Leap Medical (85)
Murray Medical Revenue: 2309 (MILLIONs of U.S dollars) April 1, Murray Medical announced its 2019 annual report, the reporting period achieved operating income of 16.556 billion yuan, 20.38 percent year-on-year, the net profit of the mother of 4.681 billion yuan, up 25.85 percent year-on-year, and the net profit of 4.615 billion yuan, up 25.04 percent year-on-year
In recent years, Murray Medical has continued to increase investment in research and development, products are constantly moving towards high-end In 2019, the company's research and development investment reached 1.65 billion, accounting for 10% of total revenue, three areas of high-end products to further achieve breakthroughs, the company's overall competitiveness continued to strengthen, further strengthening the company's medium- and long-term development foundation According to the earnings report, Murray Medical expects operating income of RMB198.72/238.73/18.660 billion yuan in 20-22
Xinhua Medical Revenue: 1206 (MILLIONs of U.S dollars) January 22, Xinhua Medical announced the 2019 annual results of the announcement According to the announcement, net profit attributable to shareholders of listed companies in 2019 increased by RMB87,492.11 million to RMB88.631million compared with the same period last year Net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, is expected to increase by RMB65.7437 million to RMB77,135.8 million compared with the same period last year Overall, the company's medical equipment, medical trade sector performance growth has risen steadily
Lepp Medical Revenue: 1114 (MILLIONs of U.S dollars) Lepu Medical's earnings announcement shows that in 2019 its revenue, net profit, net profit of non-maternal rebate stake was 7,796 million, 1.725 billion, 1.241 billion, respectively, up 22.64 percent, 41.57 percent, 18.21 percent year-on-year, overall performance growth
For 2019 results in line with expectations, Lepu Medical said this is mainly due to the traditional advantages of product growth and rich research and development pipelines At present, Lepu medical innovative equipment product line layout is complete, rich technical reserves, four innovative equipment pipelines are beginning to take shape, NeoVa degradable bracket has the advantages of international leading technology The company's strategy of "developing a generation, registering a generation, producing and selling a generation" helps to form a good gradient product line and pipeline In addition, Lepu Medical also announced a total of 3.18 billion yuan of fixed growth plan, began to accelerate the pace of international transformation
Micro-invention Medical Revenue: 752 (MILLIONs of U.S dollars) Micro-Invention Healthcare reported revenue of $793 million in 2019, up 18.5% YoY, while net profit attributable to shareholders of the parent company was $446 million, up 93.5% YoY
The company's significant improvement in performance was mainly due to significant increases in revenue from cardiovascular intervention products, arterial and peripheral vascular intervention products, heart valve business and orthopaedic medical device division business in the Chinese market, as well as the investment income from the sale of some of shanghai's micro-invasive electrophysiologic medical technology co., Ltd With the listing of micro-invasive medical products registered in 2019, it will bring corresponding earnings growth, with revenue forecast to be US$8.62/993 million in 2020/2021, a growth rate of 8.7%, 15.2%, and a net profit of US$0.56/070 million
Fish Leap Medical Revenue: 664 (MILLIONs of U.S dollars) On February 28, Fish Leap Medical reported its 2019 results, achieving total operating income of RMB4,639 million, up 10.88 percent YoY, and operating profit of RMB824 million, up 6.21% YoY Overall, in 2019, Fish Leap Medical Line business continued to maintain a steady growth of 20 plus% of the business, key products blood pressure meters, blood glucose meters and test paper, ventilators have achieved a rapid growth of 30 plus%, oxygen machine business to complete sales and product structure upgrade adjustment, business scale decreased slightly year-on-year;
Some people in the industry believe that the future with the rapid growth of online TOC business, blood glucose meter products (including test paper) and rapid growth of ventilators, the completion of the technical reform of production capacity and quality improvement, the second phase of automation base production, 2020 will be a turning point in the pace of fish leap medical operations.